Bill > S804

This bill aims to promote transparency and prevent price gouging of pharmaceutical drug prices. Key provisions include: 1. Defining "pharmaceutical manufacturing company" and "pharmacy benefit manager" to clarify covered entities. 2. Defining "pipeline drugs" as new prescription drug products containing new molecular entities. 3. Requiring the Health Policy Commission to assess pharmaceutical manufacturing companies and pharmacy benefit managers for costs related to analyzing pharmaceutical spending trends. 4. Expanding the Health Policy Commission's membership to include representatives from the pharmaceutical industry and at least one pharmacy benefit manager. 5. Requiring pharmaceutical manufacturing companies to provide early notice to the Commission on pipeline drugs, generic drugs, and biosimilar products. 6. Establishing a process for the Commission to review the pricing of certain high-cost prescription drugs and require manufacturers to submit an "access improvement plan" if the pricing substantially exceeds the Commission's proposed value. 7. Granting the Attorney General expanded authority to monitor health care market trends, investigate pharmaceutical companies and pharmacy benefit managers, and intervene in federal regulatory efforts. 8. Requiring the Center for Health Information and Analysis to promulgate regulations for more detailed reporting from pharmaceutical companies and pharmacy benefit managers on drug costs, rebates, marketing, and other financial information.

Health and Social Services

https://malegislature.gov/Bills/192/S804